VERU INC. 8-K

What Happened
VERU Inc. filed an 8-K on June 4, 2026 announcing a clinical supply agreement with Novo Nordisk A/S to support VERU’s Phase 2b PLATEAU study. VERU will sponsor and conduct the PLATEAU trial testing enobosarm (an oral SARM developed by VERU) in combination with Novo Nordisk’s Wegovy® (semaglutide) in older adults with obesity who are receiving Wegovy therapy. Novo Nordisk will supply Wegovy at no charge for use in the study; VERU retains full global development and commercialization rights to enobosarm but granted Novo Nordisk a right of first negotiation if VERU later seeks to develop, commercialize or license enobosarm in combination with any Novo Nordisk GLP‑1 product.

Key Details

• Agreement announced in an 8-K filed June 4, 2026; applies to the Phase 2b PLATEAU clinical study.
• Novo Nordisk will supply Wegovy® (semaglutide) to VERU at no charge and only for use in the PLATEAU study.
• VERU is solely responsible for conducting and sponsoring the PLATEAU trial.
• VERU granted Novo Nordisk a right of first negotiation for future development/commercialization/licensing of enobosarm combined with any Novo Nordisk GLP‑1 product.
• Filing notes Novo Nordisk’s participation is not an endorsement and contains forward‑looking statements and related risk disclosures (including a potential 60‑day convenience termination right noted among risks).

Why It Matters
For investors, the agreement reduces a key operational barrier and cost for the PLATEAU study by securing semaglutide supply from Novo Nordisk at no charge, which can help VERU advance its Phase 2b program. VERU keeps global rights to enobosarm, preserving future commercial value, but the right of first negotiation gives Novo Nordisk a prioritized chance to negotiate combination opportunities—an important strategic concession to note. The filing also highlights standard risks (trial outcomes, regulatory review, financing and potential termination), which investors should consider when assessing the impact of this collaboration on VERU’s development plan and resources.